NAV-003 / Navrogen - LARVOL DELTA

NAV-003, A Bispecific Antibody Targeting A Unique Mesothelin Epitope and CD3ε With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors. (PubMed, Eur J Immunol) - "Moreover, NAV-003 demonstrated good tolerability in mice and efficacy against patient-derived mesothelioma xenografts co-engrafted with human peripheral blood mononuclear cells. Together these data support the potential for NAV-003 clinical development and human proof-of-concept studies in patients with MSLN-expressing cancers."

Journal • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • MSLN

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting (PRNewswire) - "Navrogen...will be presenting new preclinical data on its NAV-001 antibody-drug conjugate (ADC) and NAV-003 bispecific programs at the 2023 American Association for Cancer Research (AACR) Conference....NAV-001 and NAV-003 both target mesothelin, a cell surface protein over-expressed on various malignancies, including breast, colon, lung and mesothelioma cancers....These drug candidates have demonstrated significant in vivo efficacy across a wide array of mesothelin-positive cancer models."

Preclinical • Breast Cancer • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • Thoracic Cancer